Agents that target the TH17-interleukin pathway show promise in psoriatic arthritis, as alternatives for patients who don't benefit from TNFα blockers. This slide show describes their mode of action and potential.
Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis
Emerging Agents in the Treatment of Rheumatic Diseases
Early-Onset IBD Linked to Greater Risk of Diseases with Possible Autoimmune Pathogenesis
Challenges with Step Therapy Protocols in Treating Rheumatoid Arthritis
At-Risk RA Individuals Have Different Views on Preventive Measures
Thiocyanate Exposure Linked to Greater Arthritis Risk, Heightened Inflammation Indicators